- Previous Close
0.5500 - Open
0.5335 - Bid 0.5290 x 1800
- Ask 0.5999 x 1000
- Day's Range
0.5360 - 0.6100 - 52 Week Range
0.4300 - 1.0200 - Volume
196,639 - Avg. Volume
115,151 - Market Cap (intraday)
56.059M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3600 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.37
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
www.volition.comRecent News: VNRX
View More
Performance Overview: VNRX
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VNRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VNRX
View MoreValuation Measures
Market Cap
56.06M
Enterprise Value
56.53M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
36.79
Price/Book (mrq)
--
Enterprise Value/Revenue
43.96
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-122.00%
Return on Equity (ttm)
--
Revenue (ttm)
1.29M
Net Income Avi to Common (ttm)
-29.87M
Diluted EPS (ttm)
-0.3600
Balance Sheet and Cash Flow
Total Cash (mrq)
5.41M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.97M